Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab, Paclitaxel, Cisplatin and Radiation for Locally Recurrent and Oligometastatic Endometrial Carcinoma
NCT06532539Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2024
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in endometrial carcinoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival at 60 months. Started Jun 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT06532539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532539.